Clinical Trials
59 trialsWeCan-Rural
Duke University
A Synthetic Lethality-Focused Algorithm to Identify Therapeutic Options in Advanced Metastatic Breast Cancer (SYNTHESIS-Breast)
National Institutes of Health Clinical Center (CC)
Biospecimen Collection in Identifying Genetic Changes in Patients With Breast, Prostate, Colorectal, Liver, or Kidney Cancer or Multiple Myeloma Undergoing Surgery
National Cancer Institute (NCI)
Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer
National Cancer Institute (NCI)
LoTam
Alliance for Clinical Trials in Oncology
The PhOCus Trial: Implementation of Pharmacogenomic Testing in Oncology Care
University of Chicago
COSMOPOLITAN
University Hospital Heidelberg
The Impact of Surgeon-Interpreted Intraoperative Margin Assessment During Breast Conserving Surgery on Postoperative Treatment
M.D. Anderson Cancer Center
Finding an Effective Dose of GM1 to Reduce or Prevent Neuropathy (Numbness or Weakness) Due to Treatment With Paclitaxel (Phase II)
Alliance for Clinical Trials in Oncology
Safety, Ultrasound Conspicuity, and Migration of Twinkling Markers in Patients With Locally Advanced Breast Cancer
Mayo Clinic
Paclitaxel Therapeutic Drug Monitoring in Cancer Patients
Wake Forest University Health Sciences
Fluzoparib in Combination With or Without Camrelizumab for Homologous Recombinant Deficiency (HRD) HER2 Negative Advanced Breast Cancer
Sun Yat-sen University
Hypofractionated Partial Breast Irradiation in Treating Patients With Early Stage Breast Cancer
M.D. Anderson Cancer Center
Circulating Tumor DNA Based Minimal Residual Disease Detection for Patients With Early-Stage Breast Cancer
City of Hope Medical Center
Stand up to Cancer: MAGENTA (Making Genetic Testing Accessible)
M.D. Anderson Cancer Center
Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
University of Florida
CRYOMATASE
University Hospital, Montpellier
Pilot Trial of Preop Partial Radiation in Breast Cancer Patients
Rutgers, The State University of New Jersey
Genetic Testing to Improve Management of Patients Undergoing Breast Biopsy
Mayo Clinic
A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7
NextPoint Therapeutics, Inc.
MIRROR
University of California, San Francisco
Physiotherapy Program Impact on Breast Cancer-Related Lymphedema
European University Miguel de Cervantes
Adherence Intervention in Patients With Metastatic Breast Cancer
Columbia University
Optimizing Treatment of Stage IV Breast Cancer Through Real-Time Disease Monitoring
Mayo Clinic
IPT
New York State Psychiatric Institute
Taletrectinib in Previously Treated Metastatic CDH1-mutated Invasive Lobular Cancer (ILC)
Case Comprehensive Cancer Center
Postoperative Identification of Tumor Cells At the Lumpectomy Site of Patients with Early Breast Cancer
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
RNSM
University Health Network, Toronto
Multiparametric MRI as a Non-Invasive Biomarker of the Tumor Microenviroment
Vanderbilt-Ingram Cancer Center
IMM2902, a HER2/SIRPα Bispecific MAb-Trap Antibody-receptor Fusion Protein, in Patients with HER2-expressing Advanced Solid Tumors
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage IIIC-IV Breast Cancer
Academic and Community Cancer Research United
A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Cancer
Ascentage Pharma Group Inc.
Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer
Veana Therapeutics
Diffusion-Weighted MRI for Breast Cancer Screening in Women With a Personal History of Breast Cancer
Seoul National University Hospital
DNX-2440 for Resectable Colorectal Liver Metastasis
DNAtrix, Inc.
DIRECT-2
Leiden University Medical Center
A Trial Evaluating the Efficacy and Safety of EndoTAGĀ®-1 in Combination With Paclitaxel and Gemcitabine Compared With Paclitaxel and Gemcitabine as First-line Therapy in Patients With Visceral Metastatic Triple-negative Breast Cancer
SynCore Biotechnology Co., Ltd.
Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors
Bellicum Pharmaceuticals
Guangzhou Women's Health Cohort Study (GWHCS)
Guangzhou Women and Children's Medical Center
Comparison of Two Types of Biopsy in Suspicious Axillary Lymph Nodes
Peking University People's Hospital
A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors
PACT Pharma, Inc.
Short and Long Term Effects of a Physical Therapy Program After Breast Cancer Surgery
Universidade Federal de Sao Carlos
Understanding Patient Experience and Preferences for the QT Scanner Compared to Mammography
QT Ultrasound LLC
Trial of Neoadjuvant Docetaxel ± Metronomic Capecitabine/CTX Followed by FEC in Women With Operable Triple Negative Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Real-time Diagnosis and Visualization of Tumor Margins in Excised Breast Specimens Using Zenith FLIM Diagnostics
Laser LabCorp
Predicting Response of Metastatic Triple Negative Breast Cancer to Immunotherapy Based on Patients Cytokine Profile
Texas Tech University Health Sciences Center, El Paso
Pre-operative Hormonal Treatment for Hormone Receptor Positive Breast Cancer
The Netherlands Cancer Institute
Guide for Prioritisation of Patients for Referral to Breast Clinics
The Leeds Teaching Hospitals NHS Trust
Clinical Evaluation of Opto-Acoustic Image Quality With the Gen1B Duplex Probe in Breast Applications
Seno Medical Instruments Inc.
A Study of First-line JS001 and Nab-paclitaxel Versus Palcelbo and Nab-Paclitaxel in Participants With Advanced Recurrent or Metastatic TNBC
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.